The primary purpose of this study is to determine whether a protease inhibitor-based
antiretroviral regimen is more efficacious than a non-nucleoside reverse transcriptase
inhibitor-based antiretroviral regimen in promoting the regression of KS tumor burden in
persons with AIDS-related KS in Africa.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Abbott Gilead Sciences Merck Sharp & Dohme Corp. National Institutes of Health (NIH)